Author: Bella Hayes
New York, New York–(Newsfile Corp. – January 2, 2025) – Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Southwest Airlines Co. (NYSE: NYSE:) in connection with Southwest Airlines’ information technology infrastructure impacting the Company’s business, operations, and stock price. If you currently own shares of Southwest Airlines stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=10716 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm,…
New York, New York–(Newsfile Corp. – January 1, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Humacyte securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Humacyte class action, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim,…
Not for distribution in the United States or to U.S. newswire services OTTAWA, Ontario–(BUSINESS WIRE)–Edgewater Wireless Systems Inc. (TSX-V: YFI) (OTC: KPIFF) (the Company or Edgewater Wireless) is pleased to announce the closing of its previously announced non-brokered private placement (the Private Placement). Pursuant to the Private Placement, the Company has issued a total of 38,300,000 units (the Units) at a price of $0.05 per unit for gross proceeds of $1,915,000. Please see the Company’s news releases dated December 6, 2024, December 13, 2024, and December 16, 2024. Each Unit consists of one common share in the capital of the…
Following this transaction, Schatz retains 31,366 shares of Class A common stock. In addition to his holdings in Class A stock, Schatz also holds 218,833 shares of Class B common stock. This includes 21,846 shares that are not subject to vesting or transfer restrictions, and 196,987 options to purchase Class B common stock that are fully vested and unrestricted. The $143 million market cap company offers an attractive 8.4% dividend yield, and InvestingPro analysis reveals 7 additional key insights about TSQ’s financial health and growth prospects. Get the complete picture with InvestingPro’s comprehensive research report, available for 1,400+ US stocks.…
New York, New York–(Newsfile Corp. – December 29, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Customers Bancorp, Inc. (NYSE: NYSE:) between March 1, 2024 and August 8, 2024, both dates inclusive (the “Class Period”), of the January 31, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Customers Bancorp securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join…
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX; : TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix ®1, 89Zr- girentuximab) kidney cancer imaging2. TLX250-CDx is an investigational PET3 drug product for the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in…
New York, New York–(Newsfile Corp. – December 28, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: NASDAQ:) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip…
New York, New York–(Newsfile Corp. – December 28, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Customers Bancorp, Inc. (NYSE: NYSE:) between March 1, 2024 and August 8, 2024, both dates inclusive (the “Class Period”), of the January 31, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Customers Bancorp securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join…
New York, New York–(Newsfile Corp. – December 27, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Quanterix (NASDAQ:) Corporation (NASDAQ: QTRX) resulting from allegations that Quanterix may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Quanterix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join…
Andrew Arno, a director at Oncocyte Corp (NASDAQ:OCX), recently acquired 12,500 shares of the company’s common stock at a weighted average price of $2.108 per share. This transaction, valued at approximately $26,350, took place on December 26, 2024. Following this purchase, Arno directly owns 81,554 shares. Additionally, Arno holds indirect ownership through JBA Investments LLC and MJA Investments LLC, where he serves as the manager with the right to vote and dispose of securities. InvestingPro analysis reveals the company’s current market cap stands at $35.52 million, with several additional insights available through the comprehensive Pro Research Report, which provides deep-dive…
